STATEMENT OF PURPOSE
RS27259 / H0315
The Idaho Board of Pharmacy administers the regulatory provisions of the state's Uniform Controlled
Substances Act. If any substance is designated, rescheduled, or deleted as a controlled substance under federal
law and notice thereof is given to the Board, the Board shall similarly control the substance unless the Board
objects to the inclusion, rescheduling, or deletion. This bill mirrors DEA scheduling decisions for 2019,
including placing synthetic cannabinoids, synthetic cathinones, and synthetic fentanyls in Schedule I.
FISCAL NOTE
This legislation will have no fiscal impact to the General Fund or the Board of Pharmacy's dedicated fund. It
has no fiscal impact because adding, removing, or rescheduling products to the Controlled Substances Act does
not create any new state program and does not compel any state action.
Contact:
Nicki Chopski
Board of Pharmacy
(208) 334-2356
DISCLAIMER: This statement of purpose and fiscal note are a mere attachment to this bill and prepared by a proponent
of the bill. It is neither intended as an expression of legislative intent nor intended for any use outside of the legislative
process, including judicial review (Joint Rule 18).
Statement of Purpose / Fiscal Note Bill SOP/FN INTRODUCED: 01/13/2020, 8:53 AM


Statutes affected:
Bill Text: 37-2705